AKR1C3 and cancer: Its second-generation counterpart, KV-49g, stands out as the most effective and selective AKR1C3 inhibitor known, overcoming resistance to anti-cancer agents apalutamide and darolutamide (Verma et al., 2019; Morsy and Trippier, 2020).